FATE THERAPEUTICS INC (FATE)

The company is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies. It uses an approach it calls cellular programming. It engineers human induced pluripotent stem cells (iPSCs) with synthetic controls of cell function, then generates a clonal master iPSC line as a renewable starting material. That line is differentiated into uniform T-cell and natural killer (NK) cell product candidates. The company positions this as an alternative to autologous (patient-derived) and donor-derived allogeneic cell therapies, which it says face problems with manufacturing complexity, cost, batch variability, scalability and donor variability.

Its pipeline consists of iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. FT819 is a CD19-targeted CAR T-cell candidate in a multi-center Phase 1 trial for moderate-to-severe systemic lupus erythematosus, with sites in the U.S., U.K. and EU. It received FDA regenerative medicine advanced therapy (RMAT) designation in April 2025. The trial has been expanded to include dose-expansion cohorts in systemic sclerosis, ANCA-associated vasculitis and idiopathic inflammatory myositis. The company plans a Phase 2 registration-enabling protocol in lupus nephritis. FT522 is a CD19-targeted CAR NK cell candidate for B cell-mediated autoimmune diseases, with an IND allowed by the FDA in October 2024. It incorporates a high-affinity, non-cleavable CD16 Fc receptor and the company's Alloimmune Defense Receptor technology, which is designed to reduce or eliminate the need for conditioning chemotherapy. FT825 is a multiplexed-engineered, HER2-targeted CAR T-cell candidate for solid tumors with seven synthetic controls of cell function. It is in Phase 1 development in collaboration with Ono Pharmaceutical.

The company's initial focus is patients with autoimmune diseases and cancer. In autoimmunity, it targets B cell-mediated diseases, where current options such as corticosteroids, immunosuppressants and biologics often require long-term use and fail to give adequate control. In oncology, it targets solid tumors, for which no CAR T-cell therapies are FDA-approved. It aims to make treatment more accessible, including outpatient and community settings, by avoiding apheresis and using less intense or no conditioning chemotherapy. It received MHRA authorization (August 2025) and EMA authorization (October 2025) to start FT819 trials in the U.K. and EU, and plans further expansion outside the U.S. in 2026.

The company operates a 40,000+ square foot fully integrated Good Manufacturing Practice (GMP) facility for its iPSC-derived CAR T-cell and CAR NK cell candidates, intended to support all phases of clinical development and initial commercialization. Its platform covers generating and characterizing iPSC clones, creating and cryopreserving clonal master iPSC lines, differentiating them into T and NK cells at scale, and storing the products for multi-year stability. The platform is backed by over 600 issued patents and 550 pending patent applications. The text does not identify its headquarters, suppliers or competitors.